Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2401 to 2415 of 8235 results

  1. Giredestrant with everolimus for treating oestrogen-receptor positive HER2-negative advanced breast cancer after cyclin-dependent kinase 4 and 6 inhibitor and endocrine treatment ID6576

    In development Reference number: GID-TA11773 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Fertility problems: assessment and treatment - update 1 and 2

    In development Reference number: GID-NG10263 Expected publication date:  19 March 2026

    NICE guideline
    In development

  3. Tolebrutinib for treating primary progressive multiple sclerosis [TSID12166]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  4. Zanidatamab with chemotherapy with or without tislelizumab for untreated HER2-positive unresectable advanced gastro-oesophageal adenocarcinoma [ID6672]

    Awaiting development Reference number: GID-TA11878 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Percutaneous insertion of a cerebral protection device to prevent cerebral embolism during TAVI

    In development Reference number: GID-IPG10439 Expected publication date: TBC

    Interventional procedures guidance
    In development

  6. Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments [ID6212]

    In development Reference number: GID-TA11203 Expected publication date:  08 April 2026

    Technology appraisal guidance
    In development

  7. Durvalumab in combination for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction cancer [ID6374]

    In development Reference number: GID-TA11440 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Inhaled treprostinil for treating pulmonary hypertension with interstitial lung disease [ID6459]

    In development Reference number: GID-TA11572 Expected publication date:  25 February 2026

    Technology appraisal guidance
    In development

  9. Lifileucel for previously treated unresectable or metastatic melanoma ID3863: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 22 January 2026.

    Technology appraisal guidance
    In consultation

  10. Suspected Cancer: recognition and referral (update): draft guidance consultation

    We are listening to your views on this NICE guideline. Comments close 2 February 2026.

    NICE guideline
    In consultation

  11. Familial Breast Cancer: initial assessment and genetic testing (update)

    In development Reference number: GID-NG10438 Expected publication date:  22 April 2027

    NICE guideline
    In development

  12. In-situ normothermic regional perfusion of the abdomen for donor livers following circulatory death

    In development Reference number: GID-IPG10405 Expected publication date: TBC

    Interventional procedures guidance
    In development

  13. Cyclosporin eye drops for treating moderate to severe keratoconjunctivitis [TSID12293]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  14. Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer [ID5113]

    In development Reference number: GID-TA11025 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304]

    Awaiting development Reference number: GID-TA11100 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development